Results 101 to 110 of about 226,308 (303)

Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database

Arthritis &Rheumatology, EarlyView.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty, Loubna Dari, Jean‐Luc Cracowski, Matthieu Roustit, Charles Khouri   +4 more
wiley   +1 more source

Short- and Long-Term Statin Persistence and Determinants in Patients Initiating Statin Therapy

Medeniyet Medical Journal
Objective: Despite the established efficacy of statins in reducing major cardiovascular events and mortality, rates of statin persistence remain low.
Mehmet UZUNLULU, Cundullah TORUN, Erhan EKEN, Gizem AYASGIL ULAS, Lütfullah CASTUR   +4 more
doaj   +1 more source

Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need [PDF]

, 2005
Background There is a small, but growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The aim of this paper is to further explore the equity of prescribing for five major CHD drug groups and to ...
A Gibson, A Majeed, A Majeed, A Majeed, A Williams, AM Tod, Antony S St Leger, B Hope, BH Foundation, C Baxter, C Packham, C Packham, D Health, D Health, D Health, D Health, DC Lloyd, DC Lloyd, EUROASPIREII Group., FA Majeed, FA Majeed, FDA Reid, G Davey-Smith, G Davey-Smith, GC Fonarow, H Cooper, H Tunstall-Pedoe, J Bedson, J Hippisley-Cox, J Tudor Hart, JHS Unit, JI Mann, JY Nazroo, K Gardner, M Frischer, M Goddard, M Pringle, M Whitehead, M Whitehead, MC MacLeod, MG Hunink, MG Patel, N Bradshaw, N Chaturvedi, N Danchin, N Rice, NC Campbell, NHS Centre for Reviews and Dissemination, ON Statistics, P Jousilahti, P Primatesta, P Suadicani, P Townsend, Paul R Ward, Peter R Noyce, PG Steg, PH Whincup, PR Ward, PR Ward, PR Ward, PS Unit, PS Unit, R Bhopal, R Bhopal, RM Haynes, S Hopper, S Kerrison, S Langham, S Peckham, SM Bogle, SR Chapman, SS Gottlieb, T Crayford, T Morton-Jones, T Walley, TJ Wang, V Salomaa, WH Organisation.   +77 more
core   +4 more sources

Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population‐Based Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the association between early antimalarial adherence and future acute care utilization and cost in a population‐based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022
Md Rashedul Hoque, Diane Lacaille, J. Antonio Aviña‐Zubieta, Mary A. De Vera, Yi Qian, Lawrence McCandless, John M. Esdaile, Hui Xie   +7 more
wiley   +1 more source

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial [PDF]

, 2012
Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure.
A Mercat, AM Cheung, C Brun-Buisson, C Rossi, Cecilia M O’Kane, Christine McNally, Daniel F McAuley, DJ Kor, Excellence NIfHaC, F Gao Smith, Gavin D Perkins, GD Rubenfeld, GR Bernard, Grainne Crealey, Irish Critical Care Trials Group, John G Laffey, KF Schulz, LA Curtis, Lynn Murphy, M Shyamsundar, MA Matthay, Mark Cross, Michael Stevenson, MS Herridge, RG Brower, S Harvey, SE Erickson, T Craig, The ARDS Network investigators, The EuroQol Group, TR Craig, TW Felton   +31 more
core   +1 more source

Switching statins [PDF]

BMJ, 2006
James C, Moon, Richard G, Bogle
openaire   +2 more sources

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020).
Tate M. Johnson, Halie Frideres, Punyasha Roul, Joshua F. Baker, Brian C. Sauer, Grant W. Cannon, Isaac D. Smith, Gary A. Kunkel, Beth I. Wallace, Thomas R. Porter, Kaveh R. Bookani, Amarnath R. Annapureddy, Ted R. Mikuls, Bryant R. England   +13 more
wiley   +1 more source

The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis

Implementation Science, 2017
Background In 2011, Manitoba implemented a province-wide program of physician detailing and free sampling for generic atorvastatin to increase use of this generic statin.
Heather C. Worthington, Lucy Cheng, Sumit R. Majumdar, Steven G. Morgan, Colette B. Raymond, Stephen B. Soumerai, Michael R. Law   +6 more
doaj   +1 more source

Improved Detection of Myositis‐Specific Autoantibodies Using Luciferase Immunoprecipitation Systems Assay: Comparison With Line Blot and Conventional Immunoprecipitation

Arthritis &Rheumatology, EarlyView.
Objective Myositis‐specific autoantibodies guide the diagnosis and classification of idiopathic inflammatory myopathies, but current immunoassays vary in accuracy, particularly for autoantibodies associated with interstitial lung disease. To compare the performance of the luciferase immunoprecipitation systems (LIPS) assay with line blot and ...
Peter D. Burbelo, Iago Pinal‐Fernandez, Maria Casal‐Dominguez, Xin Tian, Shijinqiu Gao, Neha Gupta, Eric W. Robbins, John A. Chiorini, Christopher A. Mecoli, Lisa Christopher‐Stine, Livia Casciola‐Rosen, Andrew L. Mammen, Sonye K. Danoff, Anthony F. Suffredini, Julio A. Huapaya   +14 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source